FDA lifts nearly two-year hold on MaaT Pharma's microbiome therapy, opens door to PhIII

Katherine Lewin

News Reporter

After nearly two years, the FDA has decided a microbiome therapy can now be tested in US patients with acute graft-versus-host disease (aGVHD), lifting a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA lifts nearly two-year hold on MaaT Pharma's microbiome therapy, opens door to PhIII

Katherine Lewin

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

FDA lifts near­ly two-year hold on MaaT Phar­ma's mi­cro­bio­me ther­a­py, opens door to PhI­II

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

FDA lifts nearly two-year hold on MaaT Pharma's microbiome therapy, opens door to PhIII